Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
The New England Journal of Medicine
|
September 21, 2012
Eltrombopag in refractory aplastic anemia
Luke Akard
Current Hematologic Malignancy Reports
|
February 29, 2016
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Lauren Caldemeyer, Michael Dugan, John Edwards, et al.
Leukemia & Lymphoma
|
March 22, 2014
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
H Jean Khoury, Jorge Cortes, Michele Baccarani, et al.
Haematologica
|
June 12, 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
Franck E Nicolini, H Jean Khoury, Luke Akard, et al.
Leukemia & Lymphoma
|
October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
Luke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib
Jorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
Jorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 21, 2007
Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis
Hillard M Lazarus, Patrick J Stiff, Jeanette Carreras, et al.
Blood
|
February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Cancer
|
January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
Jorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
The New England Journal of Medicine
|
September 21, 2012
Eltrombopag in refractory aplastic anemia
Luke Akard
Current Hematologic Malignancy Reports
|
February 29, 2016
Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Lauren Caldemeyer, Michael Dugan, John Edwards, et al.
Leukemia & Lymphoma
|
March 22, 2014
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
H Jean Khoury, Jorge Cortes, Michele Baccarani, et al.
Haematologica
|
June 12, 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
Franck E Nicolini, H Jean Khoury, Luke Akard, et al.
Leukemia & Lymphoma
|
October 6, 2015
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
Luke Akard, Hagop M Kantarjian, Franck E Nicolini, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 22, 2013
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib
Jorge E Cortes, Franck E Nicolini, Meir Wetzler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
Jorge E Cortes, Hagop M Kantarjian, Stuart L Goldberg, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 21, 2007
Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis
Hillard M Lazarus, Patrick J Stiff, Jeanette Carreras, et al.
Blood
|
February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
Cancer
|
January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
Jorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
Page
of 2